Literature DB >> 22564515

Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice?

Leonidas Alevizos1, Ilias P Gomatos, Spyridon Smparounis, Manousos M Konstadoulakis, Georgios Zografos.   

Abstract

Primary gastric lymphoma is a rare cancer of the stomach with an indeterminate prognosis. Recently, a series of molecular prognostic markers has been introduced to better describe this clinical entity. This review describes the clinical importance of several oncogenes, apoptotic genes and chromosomal mutations in the initiation and progress of primary non-Hodgkin gastric lymphoma and their effect on patient survival. We also outline the prognostic clinical importance of certain cellular adhesion molecules, such as ICAM and PECAM-1, in patients with gastric lymphoma, and we analyze the correlation of these molecules with apoptosis, angiogenesis, tumour growth and metastatic potential. We also focus on the host-immune response and the impact of Helicobacter pylori infection on gastric lymphoma development and progression. Finally, we explore the therapeutic methods currently available for gastric lymphoma, comparing the traditional invasive approach with more recent conservative options, and we stress the importance of the application of novel molecular markers in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564515      PMCID: PMC3310767          DOI: 10.1503/cjs.002310

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  85 in total

Review 1.  Caspases--their role in apoptosis and other physiological processes as revealed by knock-out studies.

Authors:  Kenneth Sadowski-Debbing; Johannes F Coy; Walter Mier; Hubert Hug; Marek Los
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2002       Impact factor: 4.291

2.  Studies on the hypomethylation of c-myc, c-Ha-ras oncogenes and histopathological changes in human gastric carcinoma.

Authors:  J Y Fang; S S Zhu; S D Xiao; S J Jiang; Y Shi; X Y Chen; X M Zhou; L F Qian
Journal:  J Gastroenterol Hepatol       Date:  1996-11       Impact factor: 4.029

3.  High incidence of BCL-6 gene rearrangement in diffuse large B-cell lymphoma of primary gastric origin.

Authors:  R Liang; W P Chan; Y L Kwong; W S Xu; G Srivastava; F C Ho
Journal:  Cancer Genet Cytogenet       Date:  1997-09

Review 4.  Role of activated host T cells in the promotion of MALT lymphoma growth.

Authors:  M Guindi
Journal:  Semin Cancer Biol       Date:  2000-10       Impact factor: 15.707

5.  Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma.

Authors:  A J Ferreri; M Ponzoni; G Pruneri; M Freschi; R Rossi; S Dell'Oro; L Baldini; R Buffa; N Carboni; E Villa; G Viale
Journal:  Int J Cancer       Date:  2001-11       Impact factor: 7.396

Review 6.  The HER-2/neu oncogene in tumors of the gastrointestinal tract.

Authors:  J S Ross; B J McKenna
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  Gastric lymphomas in Turkey. Analysis of prognostic factors with special emphasis on flow cytometric DNA content.

Authors:  Z D Aydin; I Barista; H Canpinar; A Sungur; G Tekuzman
Journal:  Cancer       Date:  2000-07-01       Impact factor: 6.860

8.  Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas. Differences between high-grade and low-grade cases.

Authors:  M Guidoboni; C Doglioni; L Laurino; M Boiocchi; R Dolcetti
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

9.  Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course.

Authors:  L Amiot; M Onno; T Lamy; C Dauriac; P Y Le Prise; R Fauchet; B Drenou
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

Review 10.  ras and human tumors.

Authors:  S Rodenhuis
Journal:  Semin Cancer Biol       Date:  1992-08       Impact factor: 15.707

View more
  7 in total

1.  A Novel Signature of Necroptosis-Associated Genes as a Potential Prognostic Tool for Head and Neck Squamous Cell Carcinoma.

Authors:  Jing Huang; Hongqi Huo; Rong Lu
Journal:  Front Genet       Date:  2022-06-09       Impact factor: 4.772

2.  Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.

Authors:  Miaoxia He; Li Gao; Shimin Zhang; Liyang Tao; Jianjun Wang; Jianmin Yang; Minghua Zhu
Journal:  Gastric Cancer       Date:  2013-11-14       Impact factor: 7.370

3.  Expression of APPL1 is correlated with clinicopathologic characteristics and poor prognosis in patients with gastric cancer.

Authors:  J S Zhai; J G Song; C H Zhu; K Wu; Y Yao; N Li
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

4.  Identification of differentially-expressed genes in intestinal gastric cancer by microarray analysis.

Authors:  Shizhu Zang; Ruifang Guo; Rui Xing; Liang Zhang; Wenmei Li; Min Zhao; Jingyuan Fang; Fulian Hu; Bin Kang; Yonghong Ren; Yonglong Zhuang; Siqi Liu; Rong Wang; Xianghong Li; Yingyan Yu; Jing Cheng; Youyong Lu
Journal:  Genomics Proteomics Bioinformatics       Date:  2014-12-11       Impact factor: 7.691

5.  Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution.

Authors:  Shengting Zhang; Li Wang; Dong Yu; Yang Shen; Shu Cheng; Li Zhang; Ying Qian; Zhixiang Shen; Qinyu Li; Weili Zhao
Journal:  World J Surg Oncol       Date:  2015-08-15       Impact factor: 2.754

6.  Non-Hodgkin Lymphoma of the jejunum presenting as perforation peritonitis: A case report.

Authors:  Suluh Darmadi; Muhammad Faruk
Journal:  Ann Med Surg (Lond)       Date:  2020-05-18

Review 7.  Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.

Authors:  Ran Zhao; Bu Young Choi; Mee-Hyun Lee; Ann M Bode; Zigang Dong
Journal:  EBioMedicine       Date:  2016-05-03       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.